Education
About Us
Working with TipRanks
Follow Us
SynAct Pharma AB (DE:8F8)
FRANKFURT:8F8
8F8 Stock Chart & Stats
€1.88
€0.06(6.50%)
At close: 4:00 PM EST
€1.88
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.74 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€110.83M
Enterprise Value€871.84M
Total Cash (Recent Filing)€68.89M
Total Debt (Recent Filing)€1.54M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Feb 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.66
Price to Sales (P/S)0.00
P/FCF Ratio-3.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.74 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €110.83M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Feb 18, 2026 which is in 67 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Oct 30, 2025. The company reported -€0.062 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.062.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.062 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.291%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
Company Description
SynAct Pharma AB
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---